Tucidinostat plus exemestane improves progression-free survival in patients with advanced, hormone receptor (+), HER2 (−) breast cancer that failed and progressed after previous endocrine therapy Jiang et al., 2019. This evidence concerns the gene NR4A1 and breast cancer.